t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma

Genes Chromosomes and Cancer

Volumn 45, Issue 2, 2006, Pages 164-168

  Fenton, James A L ^a   Schuuring, Ed ^b   Barrans, Sharon L ^a   Banham, Alison H ^c   Rollinson, Sara J ^a   Morgan, Gareth J ^d   Jack, Andrew S ^a   Van Krieken, J Han J M ^e   Kluin, Philip M ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CASE REPORT; CHROMOSOME 14; CHROMOSOME 14Q; CHROMOSOME 3; CHROMOSOME 3P; CHROMOSOME TRANSLOCATION; DNA STRAND BREAKAGE; ENHANCER REGION; GENE CONTROL; GENE LOCUS; HUMAN; IGA1 GENE; LARGE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 3; DNA PRIMERS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

EID: 31944445676     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20278     Document Type: Article

References (22)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
2. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, Jones M, Mason DY, Prime JE, Trougouboff P, Wood K, Cordell JL. 2001. The FOXP1 winged transcription factor is a novel candidate tumour suppressor gene on chromosome 3p. Cancer Res 15:8820-8829.
3. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, Farinha P, Horsman DE, Gascoyne RD. 2005. Expression of FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072.
4. Barrans SL, Fenton JAL, Banham AH, Owen RG, Jack AS. 2004. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma patients with poor outcome. Blood 104:2933-2935.
5. Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM. 1983. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219:963-967.
6. Fang J, Dagenais SL, Erickson R, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. 2000. Mutations in FOXC2 (MFH-1), a forkhead transcription factor, are responsible for the hereditary lymphedema-distichiassi syndrome. Am J Hum Genet 67:1382-1388.
7. Fenton JAL, Pratt G, Rawstron AC, Sibley K, Rothwell D, Yates Z, Dring A, Richards SJ, Ashcroft AJ, Davies FE, Owen RG, Child JA, Morgan GJ. 2003. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene 22:1103-1113.
8. Guikema JEJ, Fenton JAL, de Boer C, Kleiverda K, Brink AATP, Raap AK, Estrov Z, Schuuring E, Kluin P. 2005. Complex biallelic rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination. Genes Chromosomes Cancer 42:164-169.
9. Hans CP, Weisenberger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue micorarray. Blood 103:275-282.
10. Haralambieva E, Schuuring E, Rosati S, van Noesel C, Jansen P, Appel I, Guikema J, Wabinga H, Bleggi-Torres LF, Lam K, van den Berg E, Mellink C, van Zelderen-Bhola S, Kluin P. 2004. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer 40:10-18.
11. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. 2001. World Health Organization classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon, France: IARC Press.
12. Li C, Tucker PW. 1993. DNA-binding properties and secondary structural model of the hepatocyte nuclear factor 3/forkhead domain. Proc Natl Acad Sci USA 90:11583-11587.
13. Nardini E, Aiello A, Giardini R, Colnaghi MI, Menard S, Balsari A. 2000. Detection of aberrant isotype switch recombination in low-grade and high grade gastric MALT lymphomas. Blood 95:1032-1038.
14. Nishimura D, Swiderski R, Alward WL, Searby CC, Patil SR, Bennet SR, Kanis AB, Gastier JM, Stone EM, Sheffield VC. 1998. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet 19:140-147.
15. Palanisamy N, Abou-Elella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, Terayu-Feldstein J, Cigudosa JC, Rao PH, Sanger WG, Weisenburger DD, Chaganti RSK. 2002. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes Cancer 33:114-122.
16. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI. Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947.
17. Shaffer AL, Rosenwald A, Staudt LM. 2002. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2:920-932.
18. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. 2005. T(3;14) (p14.1q32) involving IGH and FOXP1 is a recurrent chromosomal aberration in MALT lymphoma. Leukemia 19:652-658.
19. Ueda Y, Nishida K, Miki T, Horiike S, Kaneko H, Yokota S, Misawa S, Abe T, Kashima K, Taniwaki M. 1997. Interphase detection of BCL6/IgH fusion gene in non-Hodgkin lymphoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 99:102-107.
20. Vaandrager J, Schuuring E, Kluin-Nelemans HC, Dyer MJ, Raap AK, Kluin PM. 1998. DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Blood 92:2871-2878.
21. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin PM. 2000. Interphase FISH detection of BCL-2 rearrangement using breakpoint-flanking probes. Genes Chromosomes Cancer 27:85-94.
22. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, Michaux L, Sagaert X, Marynen P, Hagemeijer A, de Wolf-Peters C. 2005. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19:1299-1305.